| 1 | Consumer Staples | XLP | +3.8% |
| 2 | Utilities | XLU | +1.6% |
| 3 | Real Estate | XLRE | +1.0% |
| 4 | Healthcare | XLV | -1.0% |
| 5 | Financials | XLF | -2.6% |
| 6 | Consumer Disc. | XLY | -2.7% |
| 7 | Materials | XLB | -5.8% |
| 8 | Industrials | XLI | -7.1% |
| 9 | Communication | XLC | -8.2% |
| 10 | Energy | XLE | -11.2% |
| 11 | Technology | XLK | -21.0% |
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. …
| Quarter | Date | EPS est. | Actual | Surprise | YoY | Rev. est. | Actual | Surprise | YoY | Copy |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3 '26 | 10/29/267:00 AM | -$0.23 | -$0.09GAAP | +60.9% | +73% | $182.4M | $193.4M | +6.0% | +16% | |
| Q2 '26 | 7/23/267:00 AM | -$0.33 | -$0.13GAAP | +60.6% | +64% | $172.6M | $183.6M | +6.4% | +16% | |
| Q1 '26 | 4/30/267:00 AM | -$0.49 | -$0.62GAAP | -26.5% | -100% | $167.8M | $174.1M | +3.7% | +12% | |
| Q4 '25 | 2/26/267:00 AM | -$0.41 | -$0.22GAAP | +46.3% | +64% | $173.2M | $174.4M | +0.7% | +8% | |
| Q3 '25 | 10/30/257:00 AM | -$0.42 | -$0.33GAAP | +21.4% | -18% | $158.3M | $167.2M | +5.6% | +8% | |
| Q2 '25 | 7/24/257:00 AM | -$0.39 | -$0.36GAAP | +7.7% | -16% | $153.5M | $158.8M | +3.4% | +6% | |
| Q1 '25 | 4/24/257:00 AM | -$0.46 | -$0.31GAAP | +32.6% | +14% | $147.0M | $155.0M | +5.4% | +12% |
GAAP = diluted EPS as filed with the SEC.